Immune System News and Research

RSS

$Atezolizumab may change treatment strategies for refractory lung cancer patients$

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

28 Sep 2015

Study may lead to new insights on use of aspirin in GI cancer

Aspirin improves survival in patients with tumours situated throughout the gastrointestinal (GI) tract, results from a large study in The Netherlands show. This is the first time that survival data from patients with tumours in different GI locations have been analysed at the same time; previously, only one type of cancer, usually colorectal, was studied.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Two-drug combination improves progression-free survival in patients with advanced melanoma

Patients with advanced melanoma skin cancer survive for longer without their disease progressing if they have been treated with a combination of two drugs, nivolumab and ipilimumab, than with either of these drugs alone. New results show that these patients also do better regardless of their age, stage of disease and whether or not they have a cancer-driving mutation in the BRAF gene.

28 Sep 2015

Interaction between rhinovirus and nasal microbiota in early life persists over time

The interaction between infections and the microbiota during infancy in the lungs could help provide clues to disease development later in life, according to the findings of a new study.

28 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Annual flu vaccine may offer protection regardless of any viral strain, says Penn State physician

Every year at this time, we hear it's time to get the flu shot. After last year's vaccine missed the mark, how does the Center for Disease Control regain the public's confidence that their predictions will hold up this year? With the facts.

26 Sep 2015

Inflammatory response could be key link between dietary fats and obesity-related diseases

An enhanced inflammatory response could be the key link between high saturated fat intake - a recognized risk factor for obesity-related disorders - and the development of diseases like type 2 diabetes and atherosclerosis.

26 Sep 2015

New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk

A new study by researchers at the Universities of Montana, Valle de México, Boise State, and North Carolina, the Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, and Centro Médico Cozumel heightens concerns over the detrimental impact of air pollution on hippocampal metabolites as early markers of neurodegeneration in young urbanites carrying an allele 4 of the apolipoprotein E gene (APOE).

26 Sep 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

Creating a new paradigm for management of yeast infections

Yeasts are unicellular microorganisms classified within the Fungi kingdom. They are well known for their use in baking, winemaking and beer brewing fermentation, but some species of yeast are opportunistic pathogens that can cause infections in humans. "Today, yeast infections are poorly understood, difficult to diagnose, and are becoming increasingly frequent and serious, affecting over 300 million people worldwide.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

H7N9 influenza vaccine failure may be due to immune camouflage, study reveals

The avian influenza A (H7N9) virus has been a major concern since the first outbreak in China in 2013. Due to its high rate of lethality and pandemic potential, H7N9 vaccine development has become a priority for public health officials. However, candidate vaccines have failed to elicit the strong immune responses necessary to protect from infection.

25 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

The National Necrotizing Fasciitis Foundation today announced that it has awarded NNFF's Lifetime Health-Science Achievement Award 2015 to John Crew, MD and Ron Najafi, PhD for "Excellence in Innovative Healthcare". Their pioneering work has improved care for patients with life-threatening 'flesh-eating' disease and other types of wounds.

25 Sep 2015

Researchers develop new blood test to diagnose coeliac disease

Diagnosis of coeliac disease requires a tissue sample from the small intestine, which can be extremely unpleasant. Researchers at the Faculty of Medicine have developed a blood test which provides a rapid, painless answer.

25 Sep 2015

Fungi research may lead to cheaper anti-cancer drugs for humans

Cheaper anti-cancer drugs for humans might ultimately stem from a new study by University of Guelph scientists into a kind of microbial "bandage" that protects yew trees from disease-causing fungi.

25 Sep 2015

DNA nanostructures provide novel applications in molecular medicine

Researchers from Aalto University have published an article in the recent Trends in Biotechnology journal. The article discusses how DNA molecules can be assembled into tailored and complex nanostructures, and further, how these structures can find uses in therapeutics and bionanotechnological applications.

25 Sep 2015

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.

25 Sep 2015

Immune System News and Research

Atezolizumab may change treatment strategies for refractory lung cancer patients

Study may lead to new insights on use of aspirin in GI cancer

Nivolumab drug improves survival for non-SQ NSCLC patients

Two-drug combination improves progression-free survival in patients with advanced melanoma

Interaction between rhinovirus and nasal microbiota in early life persists over time

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Annual flu vaccine may offer protection regardless of any viral strain, says Penn State physician

Inflammatory response could be key link between dietary fats and obesity-related diseases

New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk

Common IBD therapeutic target may protect against intestinal inflammation

Creating a new paradigm for management of yeast infections

Patients with advanced kidney cancer benefit from cabozantinib treatment

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

H7N9 influenza vaccine failure may be due to immune camouflage, study reveals

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

Researchers develop new blood test to diagnose coeliac disease

Fungi research may lead to cheaper anti-cancer drugs for humans

DNA nanostructures provide novel applications in molecular medicine

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News